talksle logo

Dedicated to increasing awareness about
systemic lupus erythematosus (SLE), disease activity and related organ damage


Do you know that organ damage can occur with low/moderate disease activity?

Read tips on monitoring subclinical activity


Are your patients under-reporting their symptoms?

Read tips on enhancing patient interactions


Are your patients with SLE still experiencing irreversible damage despite treatment?

Explore treatment considerations


What's considered a realistic goal in treating SLE?

Review current perspectives

We understand that patients with SLE can be among your most challenging cases.

Systemic lupus erythematosus (SLE) is a significant challenge for patients and healthcare providers. Even when it appears to be well‐controlled or inactive, permanent organ damage may be occurring.1,2

Managing lupus requires a multifaceted approach to patient care. One way to support patients includes probing conversations and ongoing consideration of subclinical disease activity.3 SLE treatment decisions made today could have consequences in the years ahead.4

TalkSLE is here to help you and your patients meet the challenge of lupus.

What Next?

Systemic lupus erythematosus (SLE) is a complex, challenging condition, with certain populations at risk for more severe disease.5

Learn more now

1. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176(8):708-719. Accessed February 14, 2017. 2. Urowitz MB, Gladman DD, Ibañez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012;64(1):132-137. Accessed February 14, 2017. 3. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. Accessed February 14, 2017. 4. Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford). 2012;51(3):491-498. Accessed February 14, 2017. 5. Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257. Accessed February 14, 2017.